XM does not provide services to residents of the United States of America.
R
R

RECSilicon

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Liberty Global, Crest Nicholson, NCR Voyix and Baxter International July 5 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2 000 GMT on Friday: * * Private equity firm Carlyle Group is in exclusive talks to acquire Baxter International's BAX.N kidney care spinoff Vantive for more than $4 billion, including debt, a person familiar with the matter told Reuters.
B
B
B
C
G
H
R
S
T
U
B
T

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Thyssenkrupp, Dompe Farmaceutici, Crest Nicholson Updates: BBVA July 5 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Friday: ** Thyssenkrupp TKGA.DE , Salzgitter SZGG.DE and France's Vallourec VLLP.PA are reviewing a sale of their steel joint venture HKM after they were approached by a potential buyer, Germany's largest steelmaker said.
B
B
C
G
H
R
S
T
U
B
T

Italy's Dompe not interested in possible deal with rival drugmaker Recordati

Italy's Dompe not interested in possible deal with rival drugmaker Recordati MILAN, July 5 (Reuters) - Italy's Dompe Farmaceutici is not interested in rival drugmaker Recordati RECI.MI , the biopharmaceutical group's chief executive and chairman said on Friday. "We had looked at it... it is a large company ...we are not on the file," Sergio Dompe told Reuter.
R

Recordati shares rise as investors reportedly circle CVC stake

Recordati shares rise as investors reportedly circle CVC stake MILAN, June 18 (Reuters) - Shares in Italian drugmaker Recordati RECI.MI rose almost 3% on Tuesday, boosted by a report that investment funds KKR KKR.N and TPG TPG.O had expressed preliminary interest in buying a stake in the company. Speculation about the future of Recordati has increased after majority shareholder CVC Capital Partners CVC.AS hired investment banks JP Morgan and Goldman Sachs to explore options for the pharmaceutica
R

Recordati rises after media report on KKR, TPG interest

BUZZ-Recordati rises after media report on KKR, TPG interest ** Shares in Recordati RECI.MI rise as much as 3% after Bloomberg News reported that KKR KKR.N and TPG TPG.O expressed interest in buying a stake in the Italian drugmaker ** The two investment funds, pharma company Angelini Pharma and an Abu Dhabi sovereign fund are among suitors for part or all of the 51.8% stake owned by CVC Capital Partners, Bloomberg News said on Monday, citing people familiar with the matter ** CVC declined to com
R

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.